
Yu-Mi Wi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8916539/publications.pdf Version: 2024-02-01



Υπ-Μι Μι

#	Article	IF	CITATIONS
1	Residual Lung Lesions at 1-year CT after COVID-19. Radiology, 2022, 302, 720-721.	7.3	6
2	An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward. Journal of Korean Medical Science, 2022, 37, e28.	2.5	5
3	Clinical characteristics and the diagnostic role of molecular tests in musculoskeletal infections caused by nontuberculous Mycobacterium: a single-center experience. Infection, 2022, , 1.	4.7	0
4	The epidemiology of bloodstream infection contributing to mortality: the difference between community-acquired, healthcare-associated, and hospital-acquired infections. BMC Infectious Diseases, 2022, 22, 336.	2.9	11
5	Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study. Journal of Korean Medical Science, 2022, 37, e134.	2.5	14
6	Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients > 50 Years in Korea. Journal of Korean Medical Science, 2022, 37, .	2.5	9
7	Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period. International Journal of Infectious Diseases, 2021, 102, 561-565.	3.3	46
8	Response System for and Epidemiological Features of COVID-19 in Gyeongsangnam-do Province in South Korea. Clinical Infectious Diseases, 2021, 72, 661-667.	5.8	10
9	Differences in Clinical Characteristics and Chest Images between Coronavirus Disease 2019 and Influenza-Associated Pneumonia. Diagnostics, 2021, 11, 261.	2.6	2
10	Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing Klebsiella pneumoniae clinical isolates. Journal of Microbiology, 2021, 59, 590-597.	2.8	7
11	Two Distinct Genotypes of KPC-2-Producing Klebsiella pneumoniae Isolates from South Korea. Antibiotics, 2021, 10, 911.	3.7	6
12	Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines, 2021, 9, 931.	4.4	8
13	Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. Journal of Korean Medical Science, 2021, 36, e107.	2.5	57
14	Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do. Journal of Korean Medical Science, 2021, 36, e341.	2.5	15
15	Current Strategy and Perspective View for Preventing <i>Clostridioides Difficile</i> Infection in Acute Care Facilities. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2021, 26, 70-82.	0.6	2
16	Dysfunctional accessory gene regulator (agr) as a prognostic factor in invasive Staphylococcus aureus infection: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 20697.	3.3	15
17	Potassium intake, skeletal muscle mass, and effect modification by sex: data from the 2008–2011 KNHANES. Nutrition Journal, 2020, 19, 93.	3.4	4
18	Colistin Resistance and Extensive Genetic Variations in PmrAB and PhoPQ in Klebsiella Pneumoniae Isolates from South Korea. Current Microbiology, 2020, 77, 2307-2311.	2.2	9

Yu-Mi Wi

#	Article	IF	CITATIONS
19	Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics. Antibiotics, 2020, 9, 112.	3.7	19
20	Metronidazole therapy as initial treatment of Clostridium difficile infection in patients with chronic kidney disease in Korea. Epidemiology and Infection, 2019, 147, e289.	2.1	3
21	Colistin Heteroresistance in Klebsiella Pneumoniae Isolates and Diverse Mutations of PmrAB and PhoPQ in Resistant Subpopulations. Journal of Clinical Medicine, 2019, 8, 1444.	2.4	31
22	Evaluation of the CosmosID Bioinformatics Platform for Prosthetic Joint-Associated Sonicate Fluid Shotgun Metagenomic Data Analysis. Journal of Clinical Microbiology, 2019, 57, .	3.9	59
23	Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases. Infection and Chemotherapy, 2019, 51, 245.	2.3	44
24	Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations. International Journal of Antimicrobial Agents, 2018, 51, 670-677.	2.5	22
25	Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and TreatmentÂofÂMedical Device-Associated Infections. Infectious Disease Clinics of North America, 2018, 32, 915-929.	5.1	61
26	Emergence of colistin resistance in Pseudomonas aeruginosa ST235 clone in South Korea. International Journal of Antimicrobial Agents, 2017, 49, 767-769.	2.5	31
27	Microbiological features and clinical impact of the type VI secretion system (T6SS) in <i>Acinetobacter baumannii</i> isolates causing bacteremia. Virulence, 2017, 8, 1378-1389.	4.4	57
28	Variation in formation of persister cells against colistin in Acinetobacter baumannii isolates and its relationship with treatment failure. Journal of Antimicrobial Chemotherapy, 2017, 72, 2133-2135.	3.0	17
29	Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	12
30	Effect of Early Plasma Exchange on Survival in Patients with Severe Fever with Thrombocytopenia Syndrome: A Multicenter Study. Yonsei Medical Journal, 2017, 58, 867.	2.2	29
31	Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections. Korean Journal of Internal Medicine, 2017, 32, 146-157.	1.7	7
32	High rate of colistin dependence in <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2016, 71, 2346-2348.	3.0	20
33	Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy. International Journal of Antimicrobial Agents, 2016, 48, 175-180.	2.5	12
34	Comparison of the microbiological characteristics and virulence factors of ST131 and non-ST131 clones among extended-spectrum β-lactamase–producing Escherichia coli causing bacteremia. Diagnostic Microbiology and Infectious Disease, 2016, 84, 102-104.	1.8	26
35	Case-Control Study of the Risk Factors for Acquisition of Pseudomonas and Proteus Species during Tigecycline Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 5830-5833.	3.2	3
36	<i>In Vitro</i> Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 5834-5837.	3.2	17

Yu-Mi Wi

#	Article	IF	CITATIONS
37	Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing <i>Escherichia coli</i> Sequence Type 131. Microbial Drug Resistance, 2015, 21, 463-469.	2.0	19
38	The cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus blood isolates: their association with dysfunctional accessory gene regulator (agr). Diagnostic Microbiology and Infectious Disease, 2015, 83, 286-291.	1.8	20
39	Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: Potential clinical implications of the revised CLSI interpretive criteria. International Journal of Antimicrobial Agents, 2014, 43, 456-459.	2.5	18
40	High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. International Journal of Antimicrobial Agents, 2012, 40, 108-113.	2.5	25
41	Spontaneous Bacterial Peritonitis due to Ochrobactrum anthropi: A Case Report. Journal of Korean Medical Science, 2007, 22, 377.	2.5	15